The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...
Biosimilar drugs—lower-cost alternatives to expensive biologic drugs—have the potential to slow the growth of US drug spending. However, rates of biosimilar uptake have varied across hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results